5,6,7,8-Tetrahydroindolizine-2-carboxylic acid

Catalog No.: 
ACFOAR708
CAS No.: 
16959-59-4
Molecular Formula: 
C9H11NO2
Molecular Weight: 
165.19
5,6,7,8-Tetrahydroindolizine-2-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$208.00In stockInquiry
100mg97%$309.00In stockInquiry
250mg97%$396.00In stockInquiry
1g97%$891.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5,6,7,8-Tetrahydroindolizine-2-carboxylic acid
IUPAC Name5,6,7,8-tetrahydroindolizine-2-carboxylic acid
MDL No.MFCD20542923
Molecular FormulaC9H11NO2
Molecular Weight165.19
SMILESO=C(C1=CN2CCCCC2=C1)O
InChI KeyVNKYAVPURGSAQN-UHFFFAOYSA-N
Synonym5,6,7,8-tetrahydroindolizine-2-carboxylic acid;2-Indolizinecarboxylic acid, 5,6,7,8-tetrahydro-
CAS No.16959-59-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACFOAR708 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTRMX927 route compound structure diagram
    ACTRMX927555-75-9
  2. Plus
  3. ACQEDA250 route compound structure diagram
    ACQEDA2503189-48-8In Stock
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACFOAR708 route product structure diagram
    ACFOAR70816959-59-4In Stock
Inquiry

2. ACFOAR708 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFOAR708 route product structure diagram
    ACFOAR70816959-59-4In Stock
Inquiry

3. ACFOAR708 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFOAR708 route product structure diagram
    ACFOAR70816959-59-4In Stock
Inquiry

Comments (0)